Lacidipine

Lacidipine

Clinical data
Trade names	Lacipil, Motens
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	C08CA09 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	~10%
Protein binding	>95%
Metabolism	Hepatic
Onset of action	30–50 min
Elimination half-life	13–19 hours
Excretion	Feces (~70%)
Identifiers
IUPAC name Diethyl 4-{o-[(E)-2-tert-butoxycarbonylethenyl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
JSmol)	Interactive image
SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C
InChI InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+ Key:GKQPCPXONLDCMU-CCEZHUSRSA-N
(verify)

Lacidipine (tradenames Lacipil or Motens) is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.

It was patented in 1984 and approved for medical use in 1991.^[1]

References